. 2018 Dec 28;50(2):396–404. doi: 10.1161/STROKEAHA.118.023009
© 2018 The Authors and Janssen Research & Development, LLC Permission provided by Janssen Research & Development, LLC, to publish.
Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
Table 1.
Effects of Canagliflozin on Possible Intermediate Markers of Stroke Risk
